BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23716553)

  • 1. Prognosis of patients with core binding factor acute myeloid leukemia after first relapse.
    Kurosawa S; Miyawaki S; Yamaguchi T; Kanamori H; Sakura T; Moriuchi Y; Sano F; Kobayashi T; Yasumoto A; Hatanaka K; Yanada M; Nawa Y; Takeuchi J; Nakamura Y; Fujisawa S; Shibayama H; Miura I; Fukuda T
    Haematologica; 2013 Oct; 98(10):1525-31. PubMed ID: 23716553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse.
    Kurosawa S; Yamaguchi T; Miyawaki S; Uchida N; Sakura T; Kanamori H; Usuki K; Yamashita T; Okoshi Y; Shibayama H; Nakamae H; Mawatari M; Hatanaka K; Sunami K; Shimoyama M; Fujishima N; Maeda Y; Miura I; Takaue Y; Fukuda T
    Haematologica; 2010 Nov; 95(11):1857-64. PubMed ID: 20634493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
    Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
    Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse.
    Lim ABM; Curley C; Fong CY; Bilmon I; Beligaswatte A; Purtill D; Getta B; Johnston AM; Armytage T; Collins M; Mason K; Fielding K; Greenwood M; Gibson J; Hertzberg M; Wright M; Lewis I; Moore J; Curtis D; Szer J; Kennedy G; Ritchie D
    Intern Med J; 2018 Mar; 48(3):276-285. PubMed ID: 28628276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission.
    Damiani D; Tiribelli M; Geromin A; Cerno M; Zanini F; Michelutti A; Fanin R
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1621-1626. PubMed ID: 27178373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Østgård LSG; Lund JL; Nørgaard JM; Nørgaard M; Medeiros BC; Nielsen B; Nielsen OJ; Overgaard UM; Kallenbach M; Marcher CW; Riis AH; Sengeløv H
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):314-323. PubMed ID: 29051022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.
    Hospital MA; Prebet T; Bertoli S; Thomas X; Tavernier E; Braun T; Pautas C; Perrot A; Lioure B; Rousselot P; Tamburini J; Cluzeau T; Konopacki J; Randriamalala E; Berthon C; Gourin MP; Recher C; Cahn JY; Ifrah N; Dombret H; Boissel N
    Blood; 2014 Aug; 124(8):1312-9. PubMed ID: 25006122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
    Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
    Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.
    Kuwatsuka Y; Miyamura K; Suzuki R; Kasai M; Maruta A; Ogawa H; Tanosaki R; Takahashi S; Koda K; Yago K; Atsuta Y; Yoshida T; Sakamaki H; Kodera Y
    Blood; 2009 Feb; 113(9):2096-103. PubMed ID: 19126873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
    Choi EJ; Lee JH; Kim H; Choi Y; Lee WS; Lee SM; Park JH; Park HS; Lee JH; Lee KH;
    Int J Hematol; 2021 Jun; 113(6):851-860. PubMed ID: 33655416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
    Mosna F; Papayannidis C; Martinelli G; Di Bona E; Bonalumi A; Tecchio C; Candoni A; Capelli D; Piccin A; Forghieri F; Bigazzi C; Visani G; Zambello R; Zanatta L; Volpato F; Paolini S; Testoni N; Gherlinzoni F; Gottardi M
    Am J Hematol; 2015 Jun; 90(6):515-23. PubMed ID: 25753065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.
    Kröger N; Brand R; van Biezen A; Zander A; Dierlamm J; Niederwieser D; Devergie A; Ruutu T; Cornish J; Ljungman P; Gratwohl A; Cordonnier C; Beelen D; Deconinck E; Symeonidis A; de Witte T;
    Haematologica; 2009 Apr; 94(4):542-9. PubMed ID: 19278968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world.
    Zhai Y; Wang Q; Ji L; Ren H; Dong Y; Yang F; Yin Y; Liang Z; Wang Q; Liu W; Mei Y; Zhang L; Li Y
    Cancer Med; 2023 Dec; 12(24):21592-21604. PubMed ID: 38062912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Halaburda K; Labopin M; Mailhol A; Socié G; Craddock C; Aljurf M; Beelen D; Cornelissen JJ; Bourhis JH; Labussière-Wallet H; Blaise D; Gedde-Dahl T; Gilleece M; Yakoub-Agha I; Mufti G; Esteve J; Mohty M; Nagler A
    Haematologica; 2020 Jun; 105(6):1723-1730. PubMed ID: 31439677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Salvatore D; Labopin M; Ruggeri A; Battipaglia G; Ghavamzadeh A; Ciceri F; Blaise D; Arcese W; Sociè G; Bourhis JH; Van Lint MT; Bruno B; Huynh A; Santarone S; Deconinck E; Mohty M; Nagler A
    Haematologica; 2018 Aug; 103(8):1317-1328. PubMed ID: 29748438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia.
    Schneidawind C; Hagmaier V; Faul C; Kanz L; Bethge W; Schneidawind D
    Ann Hematol; 2018 Dec; 97(12):2491-2500. PubMed ID: 30066039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cytogenetic model predicts relapse risk and survival in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation in morphologic complete remission.
    Rashidi A; Cashen AF
    Leuk Res; 2015 Jan; 39(1):77-81. PubMed ID: 25481050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
    Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
    Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
    Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.